Erman Akkus/X
Jan 14, 2025, 03:27
Erman Akkus: ACE plus+ treatments in HCC
Erman Akkus shared on X:
“ACE plus+ treatments in HCC
2 recent trials
EMERALD-1
TACE-durva-beva vs. TACE
PFS: 15 vs 8.2 mo, HR:0·77 (95% CI 0·61–0·98), p=0·032
TACE-durva vs. TACE:
PFS: 10 vs 8.2 mo
LEAP-012
TACE-pembro-lenva vs. TACE
PFS: 14.6 vs. 10 mo, HR: 0·66 (95% CI 0·51–0·8); one-sided p=0·0002
TACE plus beva alone?
TACE-atezo-beva, pilot study, NCT05776875.”
Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 3, 2025, 12:52
Mar 3, 2025, 12:50
Mar 3, 2025, 12:47
Mar 3, 2025, 12:45
Mar 3, 2025, 12:40
Mar 3, 2025, 12:18